GlassScriptPhysician profile
Timothy D Carder
NPI 1306290598
$3,169.59
in general payments reported to CMS, 2019-2025
34 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $137 · 2021: $895 · 2022: $381 · 2023: $310 · 2024: $681 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $563.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $323.74 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $261.92 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $209.30 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.22 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $193.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $144.41 | 2020-2023 | |
| Abbott Laboratories | $131.72 | 2022-2024 | Freestyle Libre 3, Proclaim, Octrode |
| Bausch Health US, LLC | $129.96 | 2022-2025 | Aplenzin |
| Exact Sciences Corporation | $100.08 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.15 | 2019 | |
| Amarin Pharma, INC. | $79.98 | 2021 | |
| Tolmar, INC. | $65.24 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $65.13 | 2020-2022 | |
| Medtronic, INC. | $64.79 | 2021-2025 | Minimed 780g |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $60.83 | 2024-2025 | Inspire |
| Abbvie INC. | $57.07 | 2021-2022 | |
| Intra-Sana Laboratories | $50.99 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boston Scientific Corporation | $40.83 | 2024 | |
| Global Blood Therapeutics, INC. | $39.34 | 2022 | |
| Antares Pharma, INC. | $33.36 | 2025 | Xyosted |
| Biohaven Pharmaceuticals, INC. | $33.33 | 2021 | |
| Daiichi Sankyo INC. | $25.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.65 | 2021 | |
| Radius Health, INC. | $23.13 | 2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $22.24 | 2024 | |
| Pfizer INC. | $21.67 | 2024 | |
| Edwards Lifesciences Corporation | $20.98 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Nevro Corp. | $18.98 | 2024 | Senza |
| Currax Pharmaceuticals LLC | $17.86 | 2024 | Onzetra Xsail, Contrave |
| Allergan, INC. | $17.77 | 2021 | |
| Horizon Therapeutics Plc | $15.69 | 2019 | |
| Cranial Technologies, INC | $13.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Carder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.